The present invention relates to encapsulation devices for cells (such as but not limited to islet cells, stem cell derived beta cells, or the like, e.g., for regulating blood glucose, or other cells or spheroids that can produce and release a therapeutic agent that is useful in the body), more particularly to encapsulation devices with oxygen sensors and an exogenous oxygen or gas delivery system creating a closed-loop system.
The present invention features systems with encapsulation devices for cells (such as islet cells or stem cell derived beta cells or the like) and sensors for real-time monitoring of cells or analytes (such as oxygen levels, glucose levels, pH, lactate levels, carbon dioxide levels, etc.). The encapsulation devices may be loaded with cells or may be empty. The systems may be operatively connected to an oxygen generator or a gas delivery system (e.g., an air pump, a chemical oxygen generator, etc.). The sensors may be optical, electrochemical, or a combination thereof.
In some embodiments, the system (e.g., encapsulation device with oxygen sensors) and oxygen generator (or gas delivery system) are in a closed loop with the sensor reader that can regulate the delivery of oxygen or other gas to the device based on the levels of oxygen that the sensor is reading from the sensors. The integration of sensors into the device (e.g., a sensor inside the device, a sensor on the outside of the device, two sensors inside the device, etc.) can help provide measurements (e.g., oxygen, glucose, lactate, pH, carbon dioxide, etc.) at various stages including, but not limited to, pre-implantation and post-implantation.
In some embodiments, the systems (e.g., encapsulation devices with sensors, e.g., oxygen sensors) of the present invention are used with oxygen delivery. In some embodiments, the systems (e.g., encapsulation devices with oxygen sensors) of the present invention are used without oxygen delivery. In some embodiments, the systems (e.g., encapsulation devices with oxygen sensors) of the present invention are temporarily oxygenated.
As used herein, the term “oxygen delivery” also includes gas delivery, e.g., air delivery. The term “oxygen generator” also refers to a gas generator.
Without wishing to limit the present invention to any theory or mechanism, it is believed that the methods, systems (e.g., encapsulation devices with oxygen sensors), devices, and compositions of the present invention may help detect and regulate oxygen levels near or within encapsulation devices and alarm if not within the desired level. If insulin secreting cells are transplanted, the system may help regulate blood glucose by ensuring that the insulin secreting cells are properly oxygenated and therefore are able to release insulin in response to glucose in an appropriate manner.
The disclosures of the following U.S. Patents are incorporated in their entirety by reference herein: U.S. Pat. No. 5,713,888; U.S. Pat. App. No. 2003/0087427.
The present invention features systems with encapsulation devices for cells (such as islet cells or stem cell derived beta cells or the like) and sensors for real-time monitoring of cells or analytes or various features of the encapsulation device like oxygen levels, pH, lactate levels, etc. The systems may be operatively connected to oxygen generators or gas/oxygen delivery systems. In some embodiments, the system (e.g., encapsulation device with oxygen sensors) and oxygen generator are in a closed loop with the sensor reader that can regulate the delivery of oxygen to the device based on the levels of oxygen that the sensor is reading from the sensors. The integration of sensors into the device (e.g., a sensor inside the device, a sensor on the outside of the device, two sensors inside the device, etc.) can help provide measurements (e.g., oxygen, glucose, lactate, pH, carbon dioxide, etc.) at various stages including, but not limited to, pre-implantation and post-implantation.
The present invention features a system comprising: an encapsulation device comprising a lumen for holding cells surrounded by a vascularization membrane; and a sensor (or two or more sensors, e.g., two sensors, three sensors, four sensors, etc.) for monitoring (e.g., real-time monitoring) of a feature of the cells housed in the encapsulation device. The feature may be oxygen levels, oxygen consumption, glucose levels, lactate levels, pH, insulin levels, the like, or a combination thereof.
In some embodiments, the sensor(s) are disposed on an outer surface of the encapsulation device, within the encapsulation device, or on other locations (e.g., inlets, outlets, etc.), or a combination thereof. For example, in some embodiments, the system comprises a sensor disposed on the outlet of the encapsulation device and a sensor disposed on the inlet of an encapsulation device.
In some embodiments, the system further comprises a bioreactor for housing the encapsulation device.
In some embodiments, the sensor comprises a pair of oxygen sensors for measuring oxygen consumption rate of the cells housed in the encapsulation device.
In some embodiments, the system further comprises an oxygen delivery system or gas delivery system operatively connected to the encapsulation device. The oxygen delivery system may comprise an implantable oxygen generator. The oxygen delivery system may comprise a wearable oxygen generator. In some embodiments, the oxygen delivery system (or gas delivery system) delivers oxygen or gas to the encapsulation device temporarily. In some embodiments, the oxygen delivery system (or gas delivery system) delivers oxygen or gas to the encapsulation device as needed. In some embodiments, the sensor is an oxygen sensor, glucose sensor, pH sensor, lactate sensor, CO2 sensor, or a combination thereof. In some embodiments, the sensors are placed such that they do not interfere with each other.
In some embodiments, the encapsulation device comprises two lumens separated by a gas channel. In some embodiments, the oxygen delivery system (or gas delivery system) is fluidly connected to the gas channel. In some embodiments, the sensor is disposed in the gas channel.
In some embodiments, the system further comprises a reader adapted to read the sensor. In some embodiments, the reader is an implantable optical reader.
The present invention also features a system comprising: an encapsulation device comprising a lumen for holding cells surrounded by a vascularization membrane; and a first oxygen sensor disposed on an outlet of the encapsulation device and a second oxygen sensor disposed on an inlet of the encapsulation device; and an oxygen delivery system operatively connected to the encapsulation device via a tube, wherein the oxygen delivery system delivers oxygen to the encapsulation device.
In some embodiments, the oxygen delivery system or gas delivery system comprises an implantable oxygen generator. In some embodiments, the oxygen delivery system comprises a wearable oxygen generator. In some embodiments, the oxygen delivery system delivers oxygen to the encapsulation device temporarily. In some embodiments, the oxygen delivery system delivers oxygen to the encapsulation device as needed. In some embodiments, the encapsulation device comprises two lumens separated by a gas channel. In some embodiments, the oxygen delivery system is fluidly connected to the gas channel. In some embodiments, the system further comprises a sensor reader for reading the sensor. In some embodiments, the sensor reader is an implantable optical reader. In some embodiments, the sensors are operatively connected to the exogenous oxygen delivery system via the sensor reader. In some embodiments, the sensor reader is physically connected to the sensor. In some embodiments, the sensor reader is not physically connected to the sensor.
In some embodiments, upon receipt of a first command from the sensor reader when the sensor reader detects an oxygen level below a threshold level, the exogenous oxygen delivery system activates and delivers oxygen to the encapsulation device. In some embodiments, the system is operatively connected to an alarm system such that an alarm is activated when the sensor reader detects an oxygen level below a threshold level. In some embodiments, upon receipt of a first command from the sensor reader when the sensor reader detects an oxygen level above a threshold level, the exogenous oxygen delivery system deactivates and ceases delivery of oxygen/gas to the encapsulation device. In some embodiments, the system is operatively connected to an alarm system such that an alarm is activated when the sensor reader detects an oxygen level above a threshold level.
In some embodiments, the sensor reader is implantable. In some embodiments, the cells housed in the encapsulation device are islet cells or stem cell derived beta cells. In some embodiments, the system helps regulate blood glucose. In some embodiments, the sensor is an optical sensor. In some embodiments, the system further comprises a detection system for detecting the optical sensor, the detection system comprising an optical reader, wherein the optical reader is constructed from a material that allows implantation of the optical reader in a subject. In some embodiments, the optical reader is implanted adjacent to a sensor. In some embodiments, the optical reader can be implanted into the subject at any depth with respect to the skin.
In some embodiments, the reader is an implantable circuit for electrochemical sensors that send signals outside the body wirelessly.
The present invention also features a method of detecting vascularization of an encapsulation device (e.g., a cell free device) according to the present invention (e.g., comprising a lumen for holding cells surrounded by a vascularization membrane and a first oxygen sensor disposed on an outlet of the encapsulation device and a second oxygen sensor disposed on an inlet of the encapsulation device). In some embodiments, the method comprises detecting oxygen levels via the sensors, wherein an increase in oxygen level above zero (or above a certain threshold level) is indicative of vascularization of the encapsulation device. In some embodiments, the encapsulation device is absent of cells.
Any feature or combination of features described herein are included within the scope of the present invention provided that the features included in any such combination are not mutually inconsistent as will be apparent from the context, this specification, and the knowledge of one of ordinary skill in the art. Additional advantages and aspects of the present invention are apparent in the following detailed description and claims.
The features and advantages of the present invention will become apparent from a consideration of the following detailed description presented in connection with the accompanying drawings in which:
Encapsulation devices are devices for holding cells or tissues. The encapsulation device (110) shown in
In some embodiments, the encapsulation devices (110) comprise a vascularization membrane (120) and immunoisolation membrane (130). In some embodiments, the encapsulation devices (110) comprise just the vascularization membrane (120).
In the examples shown in
The encapsulation devices (110) may be constructed in various shapes and sizes and with various lumen volumes. For example, in some embodiments, the lumen has a volume of about 4.5 μl. In some embodiments, the lumen has a volume of 20 μl. In some embodiments, the lumen has a volume of 40 μl. In some embodiments, the device (110) is from 4 to 5 cm in length. In some embodiments, the device (110) is from 2 to 5 cm in length, e.g., 3 cm. In some embodiments, the device (110) is from 5 to 10 cm in length. The present invention is not limited to the aforementioned dimensions and lumen volumes. For example, in some embodiments, the lumen has a volume of about 100 μl. In some embodiments, the lumen has a volume of about 200 μl. In some embodiments, the lumen has a volume from 2 to 50 μl. In some embodiments, the lumen has a volume from 10 to 100 μl. In some embodiments, the lumen has a volume from 40 to 200 pl. In some embodiments, the lumen has a volume from 100 to 300 μl. In some embodiments, the lumen has a volume from 200 to 500 μl.
In some embodiments, within the encapsulation devices (110), there may be layers of cells or tissue, e.g., multiple lumens within the device (110). For example, an encapsulation device (110) may comprise two lumens or chambers. In some embodiments, the device comprises more than two lumens or chambers, e.g., 3 chambers or lumens, 4 chambers or lumens, 5 chambers or lumens, etc.
In some embodiments, the chamber or lumen comprises a single layer of cells. In some embodiments, the chamber or lumen comprises two layers of cells. In some embodiments, the chamber comprises three or more layers of cells. In some embodiments, islet spheroids (about 150 um in size) are used (shown in
Vascularization can occur around the encapsulation devices (110).
The present invention features systems comprising encapsulation devices for cells and oxygen sensors. As shown in
The sensors used in the systems of the present invention may be oxygen sensors, glucose sensors, pH sensors, lactate sensors, carbon dioxide sensors, the like, or a combination thereof. In some embodiments, the sensors are optical sensors, electrochemical sensors, NMR sensors, or a combination thereof.
In some embodiments, the system comprises two sensors and both sensors are oxygen sensors, e.g., the sensors are adapted to allow oxygen consumption rate (OCR) measurements. The sensors are placed such that they do not interfere with each other. In some embodiments, a first oxygen sensor is disposed at an inlet (e.g., oxygen channel) of the encapsulation device, and a second oxygen sensor is disposed at an outlet of the encapsulation device. The present invention is not limited to the sensors or placements described herein. In some embodiments, the system comprises two sensors. In some embodiments, the system comprises three sensors. In some embodiments, the system comprises four sensors. In some embodiments, the system comprises five sensors. In embodiments, the system comprises six or more sensors.
The system of the present invention may further comprise a reader adapted to read one or all sensors. In some embodiments, the reader is an external reader. In some embodiments, the reader is an implantable reader (e.g., implantable optical reader).
In some embodiments, the system of the present invention further comprises an oxygen delivery system. As shown in
As previously discussed, in some embodiments, the systems of the present invention (e.g., encapsulation devices with oxygen sensors) are used with an oxygen delivery system. In some embodiments, the systems (e.g., encapsulation devices with oxygen sensors) of the present invention are used without an oxygen delivery system.
In some embodiments, the systems (e.g., encapsulation devices with oxygen sensors) of the present invention are temporarily oxygenated. For example, in some embodiments, oxygen is temporarily delivered initially (e.g., initially upon implantation) until the system is adequately vascularized. In some embodiments, oxygen may be temporarily delivered and/or oxygen levels may be variable. For example, in some embodiments, a cell type is used that benefits from a high oxygen level. In some embodiments, a cell type is used that benefits from a low oxygen level (e.g., 15% or lower). In some embodiments, an oxygen level of about 21% oxygen (e.g., 20-22%) is used, e.g., air may be used. In some embodiments, an oxygen level from 15-22% is used. In some embodiments, an oxygen level from 10-15% is used. In some embodiments, an oxygen level from 5-10% is used. In some embodiments, an oxygen level from 0-5% is used. In some embodiments, a particular oxygen level is used initially and then the oxygen level is increased or decreased at a later time. In some embodiments, oxygen is turned on and then off. In some embodiments, oxygen is turned off and then on. In some embodiments, oxygen is turned on and off in a cycle for a period of time or indefinitely. In some embodiments, oxygen level is tailored to the application to help modulate the local immune system by providing temporary oxygen. In some embodiments, oxygen levels are tailed to when vascularization occurs. In some embodiments, immature cells are transplanted, and low oxygen levels may be used initially; as the cells mature (e.g., after a particular time, e.g., 4-6 weeks), higher oxygen levels may be provided.
Without wishing to limit the present invention to any theory or mechanism, it is believed that the methods, systems, devices, and compositions of the present invention may help detect and regulate oxygen levels near or within encapsulation devices and alarm if not within the desired level. If insulin secreting cells are transplanted, the system may help regulate blood glucose by ensuring that the insulin secreting cells are properly oxygenated and therefore are able to release insulin in response to glucose in an appropriate manner.
In some embodiments, the system features a means of determining when the cells are dead (e.g., via oxygen sensors, monitoring oxygen consumption rate, etc.). Without wishing to limit the present invention to any theory or mechanism, cells are likely dead if there is generally no difference in oxygen levels inside and outside the device. Typically there is a difference (a gradient) in oxygen levels between the inside and outside of the device because oxygen is being consumed by live cells. Thus, no difference would be indicative of no oxygen consumption, thus the cells are likely dead. A bigger difference (gradient) in oxygen levels between the inside and outside of the device would indicate there are more viable cells. A user may determine how many cells are dying by determining the change in oxygen gradient.
In some embodiments, the sensors (e.g., oxygen sensors) are operatively connected to the exogenous oxygen delivery system via a sensor reader, e.g., a reader for reading the sensors. The reader may feature a microprocessor adapted to regulate the oxygen delivery of the exogenous oxygen delivery system. For example, if the microprocessor receives a first command from the reader that oxygen levels are low (e.g., below a threshold level), the microprocessor can send a command to the exogenous oxygen delivery system to increase oxygen delivery to the encapsulation device. In some embodiments, when the microprocessor receives a second command from the reader that oxygen levels are high (e.g., above a threshold level), the microprocessor can send a command to the exogenous oxygen delivery system to decrease oxygen delivery to the encapsulation device. In some embodiments, the system is operatively connected to an alarm system such that the patient is alerted when oxygen levels are low or high.
As previously discussed, the present invention also features an implantable sensor reader (e.g., implantable optical sensor reader) for reading sensors (e.g., optical sensors). In some embodiments, the implantable sensor reader is placed near or adjacent to the sensor. In some embodiments, the sensor reader can be implanted into the subject at any depth with respect to the skin. The implantable sensor reader is constructed from materials that are compatible for implantation. Note the sensor reader may not necessarily be physically connected (e.g., could be wireless).
The present invention also features methods for detecting vascularization of an encapsulation device of the present invention. The method may comprise monitoring oxygen levels (e.g., via a first oxygen sensor, a second oxygen sensor). An increase in oxygen levels without exogenous oxygen delivery may be indicative of vascularization of the encapsulation device (e.g., oxygen is delivered to the device via the blood vessels). In some embodiments, detection of vascularization may be an indication that exogenous oxygen delivery can be discontinued. The oxygen levels that would be indicative of sufficient vascularization may depend on the transplantation site. In some embodiments, it may be 1-20 mm Hg. In some embodiments, oxygen levels indicative of vascularization may be from 1-5 mm Hg. In some embodiments, oxygen levels indicative of vascularization may be from 5 to 10 mm Hg. In some embodiments, oxygen levels indicative of vascularization may be from 10 to 20 mm Hg. In some embodiments, oxygen levels indicative of vascularization may be from 15 to 25 mm Hg. In some embodiments, oxygen levels indicative of vascularization may be from 20 to 30 mm Hg. In some embodiments, oxygen levels indicative of vascularization may be from 30 to 40 mm Hg. In some embodiments, oxygen levels indicative of vascularization may be 40 mm Hg or more.
Without wishing to limit the present invention to any theory or mechanism, it is believed that the methods, systems, devices, and compositions of the present invention may help regulate blood glucose.
Implantation may be at any appropriate site, including but not limited to an arm location, a leg location, a torso location, etc.
Various modifications of the invention, in addition to those described herein, will be apparent to those skilled in the art from the foregoing description. Such modifications are also intended to fall within the scope of the appended claims. Each reference cited in the present application is incorporated herein by reference in its entirety.
Although there has been shown and described the preferred embodiment of the present invention, it will be readily apparent to those skilled in the art that modifications may be made thereto which do not exceed the scope of the appended claims. Therefore, the scope of the invention is only to be limited by the following claims. Reference numbers recited in the claims are exemplary and for ease of review by the patent office only, and are not limiting in any way. In some embodiments, the figures presented in this patent application are drawn to scale, including the angles, ratios of dimensions, etc. In some embodiments, the figures are representative only and the claims are not limited by the dimensions of the figures. In some embodiments, descriptions of the inventions described herein using the phrase “comprising” includes embodiments that could be described as “consisting of”, and as such the written description requirement for claiming one or more embodiments of the present invention using the phrase “consisting of” is met.
The reference numbers recited in the below claims are solely for ease of examination of this patent application, and are exemplary, and are not intended in any way to limit the scope of the claims to the particular features having the corresponding reference numbers in the drawings.
This application is a 371 and claims benefit of PCT/US17/60036 filed Nov. 3, 2017, which claims benefit of U.S. Patent Application No. 62/417,005, filed Nov. 3, 2016, the specification(s) of which is/are incorporated herein in their entirety by reference.
This invention was made with government support under Grant No. DK106933, awarded by NIH. The government has certain rights in the invention.
Filing Document | Filing Date | Country | Kind |
---|---|---|---|
PCT/US2017/060036 | 11/3/2017 | WO |
Publishing Document | Publishing Date | Country | Kind |
---|---|---|---|
WO2018/085714 | 5/11/2018 | WO | A |
Number | Name | Date | Kind |
---|---|---|---|
4902476 | Gordon et al. | Feb 1990 | A |
5169390 | Athayde et al. | Dec 1992 | A |
5324518 | Orth et al. | Jun 1994 | A |
5368028 | Palti | Nov 1994 | A |
5595621 | Light et al. | Jan 1997 | A |
5626561 | Butler et al. | May 1997 | A |
5713888 | Neuenfeldt et al. | Feb 1998 | A |
5741330 | Brauker | Apr 1998 | A |
5814405 | Branca et al. | Sep 1998 | A |
5837234 | Yapel et al. | Nov 1998 | A |
5843069 | Butler et al. | Dec 1998 | A |
5980889 | Butler et al. | Nov 1999 | A |
6060640 | Pauley et al. | May 2000 | A |
6143293 | Weiss et al. | Nov 2000 | A |
6156305 | Brauker et al. | Dec 2000 | A |
6197575 | Griffith et al. | Mar 2001 | B1 |
6562616 | Toner et al. | May 2003 | B1 |
7659219 | Biran et al. | Feb 2010 | B2 |
7899927 | Vardi et al. | Feb 2011 | B1 |
8278106 | Martinson et al. | Oct 2012 | B2 |
8518123 | Jensen et al. | Aug 2013 | B2 |
8647861 | Ingber et al. | Feb 2014 | B2 |
9433557 | Green et al. | Sep 2016 | B2 |
10695379 | Greenwood et al. | Jun 2020 | B2 |
11033666 | Ferrante et al. | Jun 2021 | B2 |
20030054544 | Gruenberg | Mar 2003 | A1 |
20030087427 | Colton et al. | May 2003 | A1 |
20030129736 | Mitrani | Jul 2003 | A1 |
20040010320 | Huckle et al. | Jan 2004 | A1 |
20040024342 | Weitzel et al. | Feb 2004 | A1 |
20040133188 | Vardi et al. | Jul 2004 | A1 |
20040166141 | Cerami et al. | Aug 2004 | A1 |
20040197374 | Rezania et al. | Oct 2004 | A1 |
20050136092 | Rotem et al. | Jun 2005 | A1 |
20050221485 | Bader | Oct 2005 | A1 |
20050267440 | Herman et al. | Dec 2005 | A1 |
20060013835 | Anderson et al. | Jan 2006 | A1 |
20060019333 | Rodgers et al. | Jan 2006 | A1 |
20070061015 | Jensen et al. | Mar 2007 | A1 |
20070066138 | Ferrari et al. | Mar 2007 | A1 |
20080021436 | Wolpert | Jan 2008 | A1 |
20090074832 | Zussman et al. | Mar 2009 | A1 |
20090110669 | Schneiderman et al. | Apr 2009 | A1 |
20100082114 | Gingras et al. | Apr 2010 | A1 |
20100124564 | Martinson et al. | May 2010 | A1 |
20100130916 | Stern et al. | May 2010 | A1 |
20100160760 | Shults et al. | Jun 2010 | A1 |
20100172952 | Srouji et al. | Jul 2010 | A1 |
20100196439 | Beck et al. | Aug 2010 | A1 |
20100228110 | Tsoukalis | Sep 2010 | A1 |
20100240117 | Ying et al. | Sep 2010 | A1 |
20100255059 | Marquez et al. | Oct 2010 | A1 |
20110054589 | Bashiri et al. | Mar 2011 | A1 |
20110092949 | Wang | Apr 2011 | A1 |
20120245705 | Hasilo et al. | Sep 2012 | A1 |
20130289540 | Zeltser et al. | Oct 2013 | A1 |
20130344131 | Lo et al. | Dec 2013 | A1 |
20140014226 | Green et al. | Jan 2014 | A1 |
20140039383 | Dobbles et al. | Feb 2014 | A1 |
20140051162 | Nankervis | Feb 2014 | A1 |
20140052095 | Dobbles et al. | Feb 2014 | A1 |
20140088347 | Frigstad et al. | Mar 2014 | A1 |
20140257515 | So et al. | Sep 2014 | A1 |
20140308315 | Knezevich et al. | Oct 2014 | A1 |
20150129497 | Humes et al. | May 2015 | A1 |
20150112247 | Tempelman et al. | Aug 2015 | A1 |
20150273200 | Rotem | Oct 2015 | A1 |
20150320836 | Itkin-Ansari et al. | Nov 2015 | A1 |
20150359472 | Botvinick et al. | Dec 2015 | A1 |
20160022180 | Joseph et al. | Jan 2016 | A1 |
20160123848 | Griffin et al. | May 2016 | A1 |
20160184569 | Lathuiliere | Jun 2016 | A1 |
20170072074 | Gladnikoff et al. | Mar 2017 | A1 |
20170173262 | Veltz | Jun 2017 | A1 |
20180000395 | Lucisano | Jan 2018 | A1 |
20180126134 | Cully et al. | May 2018 | A1 |
20180263238 | Flanagan et al. | Sep 2018 | A1 |
20180298343 | Sivakumaran | Oct 2018 | A1 |
20180318566 | Ferrante et al. | Nov 2018 | A1 |
20180344665 | Isenburg et al. | Dec 2018 | A1 |
20190076840 | Gottardi | Mar 2019 | A1 |
20190136176 | Kawachi et al. | May 2019 | A1 |
20190211294 | Karnieli | Jul 2019 | A1 |
20190336267 | Tempelman et al. | Nov 2019 | A1 |
20200054257 | Papas | Feb 2020 | A1 |
20200063085 | Papas | Feb 2020 | A1 |
Number | Date | Country |
---|---|---|
3042709 | Aug 2018 | CA |
101123984 | Feb 2008 | CN |
102012390 | Apr 2011 | CN |
203915611 | Nov 2014 | CN |
105163688 | Dec 2015 | CN |
105792775 | Jul 2016 | CN |
0344314 | Dec 1989 | EP |
1351623 | Jan 2005 | EP |
2508212 | Oct 2012 | EP |
H06-205665 | Jul 1994 | JP |
2004-530431 | Oct 2004 | JP |
2014-514942 | Jun 2014 | JP |
10-2016-0094391 | Aug 2016 | KR |
WO 9100119 | Jan 1991 | WO |
WO 02100335 | Dec 2002 | WO |
WO 2006106506 | Oct 2006 | WO |
WO 2008100559 | Aug 2008 | WO |
WO2010061387 | Jun 2010 | WO |
WO 2012136701 | Oct 2012 | WO |
WO2015145264 | Oct 2015 | WO |
WO2018067813 | Apr 2018 | WO |
WO 2018089397 | May 2018 | WO |
WO2018085714 | May 2018 | WO |
WO2018102077 | Jun 2018 | WO |
WO2018144098 | Aug 2018 | WO |
WO2018144099 | Aug 2018 | WO |
Entry |
---|
Official Action for Australian Patent Application No. 2017355528, dated Aug. 20, 2020, 5 pages. |
Official Action for Australian Patent Application No. 2017396753, dated Jul. 23, 2020, 4 pages. |
Lathuiliere et al. “Encapsulated Cellular Implants for Recombinant Protein Delivery and Therapeutic Modulation of the Immune System.” International Journal of Molecular Sciences. May 2015 (May 8, 2015). vol. 16. pp. 10578-10600. |
Lee et al. Cytokines in Cancer Immunotherapy. Cancers 2011, 3, 3856-3893. |
Manickavasagam et al. Critical Assessment of Implantable Drug Delivery Devices in Glaucoma Management. Journal of Drug Delivery. vol. 2013, Article ID 895013, pp. 1-12. |
Makadia et al. Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier. Polymers (Basel). Sep. 1, 2011; 3(3): 1377-1397. |
Gholipourmalekabadi et al. Oxygen-Generating Biomaterials: A New, Viable Paradigm for Tissue Engineering? Trends in Biotechnology, Dec. 2016, vol. 34, No. 12. |
Geller et al. Use of an Immunoisolation Device for Cell Transplantation and Tumor Immunotherapy. Annals New York Academy of Sciences. pp. 438-451. |
International Search Report for PCT Application No. PCT/US17/55334 dated Dec. 26, 2017. |
Carlsson et al. Transplantation of macroencapsulated human islets within the bioartificial pancreas βAir to patients with type 1 diabetes mellitus. Am J Transplant. 2018;18:1735-1744. |
ViaCyte CEO Paul Laikind Interview: Trial Update, Melton's Concerns, & Future. https://ipscell.com/2015/03/viacyte/. |
International Search Report for PCT Application No. PCT/US17/60036 dated Feb. 16, 2018. |
International Search Report for PCT Application No. PCT/US17/60034 dated Jul. 12, 2018. |
International Search Report for PCT Application No. PCT/US17/60041 dated Jul. 10, 2018. |
International Search Report for PCT Application No. PCT/US17/60043 dated Jun. 14, 2018. |
“Membrane Basics,” PermSelect—Silicone Gas Exchange Membranes, 2021, retrieved from https://www.permselect.com/membranes, 9 pages. |
Notice of Acceptance for Australia Patent Application No. 2017396753, dated Apr. 20, 2021, 4 pages. |
Official Action (with English translation) for China Patent Application No. 201780081104.1, dated Apr. 2, 2021, 10 pages. |
Official Action for U.S. Appl. No. 16/347,388, dated May 11, 2021, 10 pages. |
Official Action for U.S. Appl. No. 16/347,147, dated Jul. 2, 2021, 12 pages. |
U.S. Appl. No. 16/347,388, filed May 3, 2019, Papas. |
Extended European Search Report for European Patent Application No. 17866485.0, dated Apr. 25, 2020, 9 pages. |
Extended European Search Report for European Patent Application No. 17895433.5, dated Apr. 17, 2020, 7 pages. |
Extended European Search Report for European Patent Application No. 17894862.6, dated May 20, 2020, 4 pages. |
Official Action for Australian Patent Application No. 2017366791, dated Jun. 22, 2020, 4 pages. |
Extended European Search Report for European Patent Application No. 17875181.4, dated Apr. 28, 2020, 4 pages. |
Krishnan et al., “Islet and Stem Cell Encapsulation for Clinical Transplantation,” Review of Diabetic Studies, vol. 11, No. 1, 2014, pp. 84-101. |
Wang et al., “Overcoming foreign-body reaction through nanotopography: Biocompatibility and Immunoisolation properties of a nanofibrous membrane,” Biomaterials, vol. 102, Sep. 30, 2016, pp. 249-258. |
Official Action for Australian Patent Application No. 2017355528, dated Nov. 16, 2020, 4 pages. |
Notice of Acceptance for Australian Patent Application No. 2017355528, dated Mar. 22, 2021, 4 pages. |
Official Action for Chinese Patent Application No. 201780081318.9, dated Feb. 1, 2021, 8 pages. |
Official Action for Australian Patent Application No. 2017396753, dated Jan. 27, 2021, 5 pages. |
Official Action for Australian Patent Application No. 2017396754, dated Nov. 12, 2020, 7 pages. |
Official Action for Chinese Patent Application No. 201780081103.7, dated Jan. 11, 2021, 11 pages. |
Notice of Allowance for Australian Patent Application No. 2017366791, dated Jan. 8, 2021, 4 pages. |
International Search Report and Written Opinion for International (PCT) Patent Application No. PCT/US2019/052728, dated Dec. 13, 2019, 10 pages. |
Official Action for U.S. Appl. No. 16/347,147, dated Apr. 8, 2021, 8 pages. Restriction Requirement. |
Official Action for U.S. Appl. No. 16/347,160, dated Dec. 28, 2020, 15 pages. |
Official Action for Korea Patent Application No. 10-2019-7015936, dated Jul. 25, 2022, 5 pages. |
Official Action for China Patent Application No. 201780081104.1, dated Jun. 30, 2022, 27 pages. |
Notice of Allowance for Korea Patent Application No. 10-2019-7015935, dated Jul. 25, 2022, 3 pages. |
Notice of Allowance for Korea Patent Application No. 10-2019-7015937, dated Jul. 22, 2022, 3 pages. |
Official Action for China Patent Application No. 201780081105.6, dated Sep. 29, 2022, 8 pages. |
Official Action for Australia Patent Application No. 2019346547, dated Sep. 2, 2022, 4 pages. |
Extended European Search Report for Europe Patent Application No. 19867716.3, dated Oct. 6, 2022, 12 pages. |
Official Action (with English summary) for Japan Patent Application No. 2021-540389, dated Jun. 21, 2022, 7 pages. |
Official Action for U.S. Appl. No. 16/347,160, dated Jul. 7, 2022, 14 pages. |
Official Action for U.S. Appl. No. 17/876,302, dated Oct. 25, 2022, 22 pages. |
Official Action for Australia Patent Application No. 2021204321, dated Jun. 6, 2022, 3 pages. |
Official Action for China Patent Application No. 201780081318.9, dated Sep. 1, 2021, 12 pages. |
Official Action for China Patent Application No. 201780081318.9, dated Apr. 7, 2022, 22 pages. |
Official Action for Korea Patent Application No. 10-2019-7015936, dated Feb. 22, 2022, 11 pages. |
Official Action for Australia Patent Application No. 202106840, dated Jun. 6, 2022, 3 pages. |
Official Action for China Patent Application No. 201780081104.1, dated Dec. 2, 2021, 11 pages. |
Official Action for Korea Patent Application No. 10-2019-7015935, dated Feb. 8, 2022, 9 pages. |
Notice of Allowance for Australian Patent Application No. 2017396754, dated Jul. 21, 2021, 4 pages. |
Official Action for China Patent Application No. 201780081103.7, dated Nov. 1, 2021, 11 pages. |
Notice of Allowance for China Patent Application No. 201780081103.7, dated Mar. 23, 2022, 2 pages. |
Official Action for Korea Patent Application No. 10-2019-7015937, dated Jan. 12, 2022, 14 pages. |
Notice of Allowance for Korea Patent Application No. 10-2019-7015937, dated May 20, 2022, 6 pages. |
Official Action for China Patent Application No. 201780081105.6, dated Aug. 9, 2021, 12 pages. |
Official Action for China Patent Application No. 201780081105.6, dated Mar. 24, 2022, 12 pages. |
Official Action for Korea Patent Application No. 10-2019-7015938, dated Sep. 30, 2021, 5 pages. |
International Preliminary Report on Patentability for International (PCT) Application No. PCT/US2019/052728, dated Apr. 1, 2021, 9 pages. |
Official Action for Australia Patent Application No. 2019346547, dated Feb. 9, 2022, 4 pages. |
Official Action for Canada patent Application No. 3114197, dated Jun. 6, 2022, 6 pages. |
Partial Supplementary European Search Report for Europe Patent Application No. 19867716.3, dated May 23, 2022, 13 pages. |
Official Action for India Patent Application No. 202117012735, dated Feb. 11, 2022, 5 pages. |
Invitation to Pay additional Fees for International (PCT) Patent Application No. PCT/US2021/057526, dated Jan. 5, 2022, 3 pages. |
International Search Report and Written Opinion for International (PCT) Patent Application No. PCT/US2021/057526, dated Mar. 2, 2022, 16 pages. |
Official Action for U.S. Appl. No. 16/347,388, dated Oct. 4, 2021, 10 pages. |
Notice of Allowance for U.S. Appl. No. 16/347,388, dated May 12, 2022, 10 pages. |
Corrected Notice of Allowance for U.S. Appl. No. 16/347,388, dated May 20, 2022, 6 pages. |
Official Action for U.S. Appl. No. 16/347,147, dated Nov. 12, 2021, 11 pages. |
Official Action for U.S. Appl. No. 16/347,147, dated Jun. 2, 2022, 14 pages. |
Official Action for U.S. Appl. No. 16/347,160, dated Nov. 29, 2021, 14 pages. |
Official Action for U.S. Appl. No. 17/387,595, dated Nov. 10, 2021, 15 pages. |
Official Action for U.S. Appl. No. 17/387,595, dated Mar. 28, 2022, 18 pages. |
Suszynski et al., “Assessment of Tissue-Engineered Islet Graft Viability by Fluorine Magnetic Resonance Spectroscopy,” Transplant Proc., vol. 43, No. 9, Nov. 2011, pp. 3221-3225. |
Number | Date | Country | |
---|---|---|---|
20190328289 A1 | Oct 2019 | US |
Number | Date | Country | |
---|---|---|---|
62417005 | Nov 2016 | US |